^
Association details:
| Biomarker: | EGFR mutation |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug Class: | PD-L1 inhibitor + CD73 inhibitor |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Anti-PD-L1 and anti-CD73 combination therapy promotes T cell response to EGFR-mutated NSCLC
Published date:
02/08/2022
Excerpt:
In a xenograft mouse model of EGFR-mutated NSCLC, neither anti-PD-L1 nor anti-CD73 antibody alone inhibited tumor growth compared with the isotype control. In contrast, the combination of both antibodies significantly inhibited tumor growth…these results further support the combination of anti-CD73 and anti-PD-L1 therapies in treating EGFR-mutated NSCLC, while suggesting that increased T cell activity may play a role in response to therapy.
DOI:
10.1172/jci.insight.142843
Source:
Title:
911 / 13 - Anti-PD-L1 and anti-CD73 combination therapy promotes T cell response to EGFR mutant NSCLC
Published date:
05/27/2020
Excerpt:
...mice treated with anti-CD73 and anti-PD-L1 combination therapy had significantly smaller tumors compared to mice treated with isotype control (~38%, p<0.0001), anti-PD-L1 alone (~32%, p<0.0001) or anti-CD73 alone (~32%, p<0.01)... these results further support the ongoing clinical trials evaluating combination of anti-CD73 and anti-PD-L1 in treating EGFR mutant NSCLC.
